US2008181902A1PendingUtilityA1

Prevention and treatment of alzheimer's disease

61
Assignee: LANNFELT LARSPriority: Jul 7, 2000Filed: Mar 19, 2008Published: Jul 31, 2008
Est. expiryJul 7, 2020(expired)· nominal 20-yr term from priority
Inventors:Lars LannfeltCamilla NilsberthAnita CampbellJan Naslund
A61P 37/04C07K 14/4711A61P 25/00A61K 38/00A61P 25/28A61P 25/16A61K 2039/505
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with high protofibril forming activity as well as several applications thereof, such as antibodies against said peptide for passive immunisation against AD.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . An antibody suitable for prevention or treatment of an α-synuclein-related disorder, wherein said antibody binds protofibrils comprising an α-synuclein peptide. 
     
     
         23 . The antibody according to  claim 22 , wherein said antibody is monoclonal. 
     
     
         24 . The antibody according to  claim 22 , wherein said antibody is humanized. 
     
     
         25 . The antibody according to  claim 22 , wherein said antibody binds protofibrils comprising an α-synuclein peptide comprising an Ala53Thr and/or Ala30Pro mutation. 
     
     
         26 . A method of preventing or treating an α-synuclein-related disorder, comprising the step of administering, to a patient having or suspected of having an α-synuclein-related disorder, the antibody according to  claim 22 . 
     
     
         27 . The method according to  claim 26 , wherein said alpha-synuclein-related disorder is selected from a group of disorders comprised of Parkinson's disease, dementia with Lewy Bodies, Lewy neuritis, Alzheimer's disease or Lewy Body Pathology. 
     
     
         28 . The method of producing the antibody according to  claim 22 , comprising the steps of: immunizing a non-human animal with a protofibril comprising an α-synuclein peptide, such that antibodies against said protofibril are generated; and extracting said antibodies from said non-human animal. 
     
     
         29 . The method according to  claim 28 , wherein said protofibril further comprises an Ala53Thr and/or Ala30Pro mutation. 
     
     
         30 . The method according to  claim 28 , wherein said antibody is monoclonal. 
     
     
         31 . The method according to  claim 28 , wherein said antibody is humanized.

Join the waitlist — get patent alerts

Track US2008181902A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.